Ovid Therapeutics Inc.(OVID)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Ovid Therapeutics Inc. (OVID) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OVID at 26.4/100 on a 32-signal composite quality model, placing it at rank #2,623 of 2,960 stocks — the bottom half of the AI-ranked universe. OVID scores in the top quartile across revenue growth (95.9). Areas of concern include revenue scale (0.6) and free cash flow (0.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Ovid Therapeutics Inc. reports quarterly revenue of $733.0K, net income of $-15.0M. Top institutional holders of OVID by reported 13-F value include Jupiter Topco, EVENTIDE ASSET MANAGEMENT, BlackRock, based on the most recent SEC filings. OVID trades on the Nasdaq exchange and files with the SEC under CIK 1636651. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OVID daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ovid Therapeutics Inc. directly from SEC EDGAR.